Literature DB >> 2266373

Multiple sclerosis in Australia and New Zealand: are the determinants genetic or environmental?

D H Miller1, S R Hammond, J G McLeod, G Purdie, D C Skegg.   

Abstract

The prevalence of multiple sclerosis (MS) has been recently reported from nine regions of Australia and New Zealand. There is a marked variation of prevalence with latitude. MS is seven times more common in southern New Zealand than in tropical Queensland. On current evidence, it is suggested that in both countries this variation is predominantly due to environmental rather than genetic factors.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2266373      PMCID： PMC488255          DOI： 10.1136/jnnp.53.10.903

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  14 in total

1.  The distribution of multiple sclerosis in the United Kingdom.

Authors:  R J Swingler; D Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-10       Impact factor: 10.154

2.  The prevalence of multiple sclerosis in New Zealand.

Authors:  R W Hornabrook
Journal:  Acta Neurol Scand       Date:  1971       Impact factor: 3.209

3.  Frequency of multiple sclerosis in three Australian cities--Perth, Newcastle, and Hobart.

Authors:  M G McCall; T L Brereton; A Dawson; K Millingen; J M Sutherland; E D Acheson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1968-02       Impact factor: 10.154

4.  Occurrence of multiple sclerosis in the north and south of New Zealand.

Authors:  D C Skegg; P A Corwin; R S Craven; J A Malloch; M Pollock
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-02       Impact factor: 10.154

5.  HLA and multiple sclerosis in south east Wales.

Authors:  R J Swingler; P F Kirk; C Darke; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-09       Impact factor: 10.154

6.  The prevalence of multiple sclerosis in Queensland, Australia. A field survey.

Authors:  J M Sutherland; J H Tyrer; M J Eadie; J H Casey; L T Kurland
Journal:  Acta Neurol Scand       Date:  1966       Impact factor: 3.209

7.  Multiple sclerosis in the Orkney and Shetland Islands. I: Epidemiology, clinical factors, and methodology.

Authors:  D C Poskanzer; L B Prenney; J L Sheridan; J Y Kondy
Journal:  J Epidemiol Community Health       Date:  1980-12       Impact factor: 3.710

8.  The epidemiology of multiple sclerosis in Queensland, Australia.

Authors:  S R Hammond; C de Wytt; I C Maxwell; P J Landy; D English; J G McLeod; M G McCall
Journal:  J Neurol Sci       Date:  1987-09       Impact factor: 3.181

9.  Intravenous paraldehyde for seizure control in newborn infants.

Authors:  G Koren; W Butt; P Rajchgot; J Mayer; H Whyte; K Pape; S M MacLeod
Journal:  Neurology       Date:  1986-01       Impact factor: 9.910

10.  Ethnic and HLA patterns related to multiple sclerosis in Wellington, New Zealand.

Authors:  D H Miller; R W Hornabrook; J Dagger; R Fong
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-01       Impact factor: 10.154
View more
  21 in total

Review 1.  Multiple sclerosis, vitamin D, and HLA-DRB1*15.

Authors:  Lahiru Handunnetthi; Sreeram V Ramagopalan; George C Ebers
Journal:  Neurology       Date:  2010-06-08       Impact factor: 9.910

2.  Migration and multiple sclerosis in United Kingdom and Ireland immigrants to Australia: a reassessment. II. Characteristics of early (pre-1947) compared to later migrants.

Authors:  J G McLeod; S R Hammond; J F Kurtzke
Journal:  J Neurol       Date:  2011-09-23       Impact factor: 4.849

3.  Multiple sclerosis: nature or nurture?

Authors:  D C Skegg
Journal:  BMJ       Date:  1991-02-02

Review 4.  Treatment update in multiple sclerosis.

Authors:  Katrina Morris; Con Yiannikas
Journal:  Curr Allergy Asthma Rep       Date:  2012-06       Impact factor: 4.806

5.  Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates.

Authors:  D M Freedman; M Dosemeci; M C Alavanja
Journal:  Occup Environ Med       Date:  2000-06       Impact factor: 4.402

6.  CD8(+) T cells are not necessary for 1 alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice.

Authors:  Terrence F Meehan; Hector F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

7.  IL7Rα contributes to experimental autoimmune encephalomyelitis through altered T cell responses and nonhematopoietic cell lineages.

Authors:  Jessica J Ashbaugh; Roberta Brambilla; Shaffiat A Karmally; Cecilia Cabello; Thomas R Malek; John R Bethea
Journal:  J Immunol       Date:  2013-03-25       Impact factor: 5.422

8.  Schistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis.

Authors:  Anne Camille La Flamme; Kate Ruddenklau; B Thomas Bäckström
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

Review 9.  Temporal trends in the incidence of multiple sclerosis: a systematic review.

Authors:  Alvaro Alonso; Miguel A Hernán
Journal:  Neurology       Date:  2008-07-08       Impact factor: 9.910

Review 10.  Neuropsychological aspects of multiple sclerosis.

Authors:  J C Brassington; N V Marsh
Journal:  Neuropsychol Rev       Date:  1998-06       Impact factor: 7.444
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.